Methods for assessing neurodevelopment in lysosomal storage diseases and related disorders: a multidisciplinary perspective

Lysosomal storage diseases and related disorders (LSRDs) are a heterogeneous group of rare diseases caused by genetic mutations that result in deficiencies of specific lysosomal enzymes. Some of these enzymes are necessary for normal development of the central and peripheral nervous systems. Because...

Full description

Saved in:
Bibliographic Details
Published in:Acta Paediatrica 2008-04, Vol.97 (s457), p.69-75
Main Authors: Martin, Holly R, Poe, Michele D, Reinhartsen, Debra, Pretzel, Rebecca E, Roush, Jackson, Rosenberg, Angela, Dusing, Stacey C, Escolar, Maria L
Format: Article
Language:English
Subjects:
Biological and medical sciences
Cognition Disorders - etiology
General aspects
Hearing Disorders - etiology
Humans
Intelligence Tests
Language Disorders - etiology
Lysosomal storage diseases
Lysosomal Storage Diseases - complications
Lysosomal Storage Diseases - psychology
Medical sciences
Neurodevelopmental outcomes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lysosomal storage diseases and related disorders (LSRDs) are a heterogeneous group of rare diseases caused by genetic mutations that result in deficiencies of specific lysosomal enzymes. Some of these enzymes are necessary for normal development of the central and peripheral nervous systems. Because of the heterogeneity in clinical presentation and complexity of these disorders, evaluation of disease progression poses unique challenges. In recent years, recombinant enzyme replacement therapy and haematopoietic stem cell transplantation have been developed to treat some of these diseases. With the development of specific therapies and screening programmes, there is a need to systematically follow the natural course and effects of treatment in these disorders with standardized and validated tools. This review describes the limitations of currently available neurobehavioural tools in longitudinally tracking disease outcomes in patients with neurodegenerative LSRDs. A multidisciplinary team reviewed over 750 evaluations in 274 patients. These patients were found to have neurological, sensory and somatic problems that considerably influence the results of neurobehavioural testing. Conclusion: Treatment effects in patients with neurodegenerative LSRDs are best evaluated by repeated measures and longitudinal analysis of each domain of function.
ISSN:0803-5253
1651-2227
DOI:10.1111/j.1651-2227.2008.00651.x